FDA Category 2 · restricted from compounding

This compound is on the FDA’s interim Section 503A Category 2 bulks list and cannot be legally compounded by US pharmacies. An HHS announcement in February 2026 signaled intent to restore several peptides to Category 1, but no Federal Register action has been published. Check the FDA PCAC schedule for updates.

ExperimentalGrowth HormoneOralDailyPartial data

AOD-9604 (Capsule)

Oral capsule form of AOD-9604 with limited bioavailability compared to injectable form.

Read dosing protocol

§ 01 Overview

Overview

Oral capsule form of AOD-9604 with limited bioavailability compared to injectable form.

Essentially no controlled bioavailability or outcome data.

§ 02 Mechanism

Mechanism of action

Oral AOD-9604 is subject to significant GI degradation. Bioavailability is much lower than subcutaneous administration; effective dosing is not well characterized.

01Convenience of oral dosing

§ 03 Dosing

Dosing protocol

Standard Protocol

Dose Range: 200 mcg (typical capsule)
Route: Oral
Timing: AM
Frequency: Daily

§ 04 Evidence

Evidence & research

Experimental

Essentially no controlled bioavailability or outcome data.

FDA Status

Not FDA-approved.

§ 07 Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09 Safety

Safety & side effects

Side effects

01Unknown due to absorption uncertainty

Contraindications

None specified.

◆ In this categoryMore from Growth Hormone

Ipamorelin

Selective ghrelin receptor agonist that releases GH without meaningfully raising cortisol or prolactin. The cleanest GHRP.

Growth HormonePreclinical

CJC-1295 (No DAC)

Short-acting GHRH analog that amplifies natural GH pulses. Almost always paired with a GHRP like Ipamorelin.

Growth HormonePreclinical

Tesamorelin

FDA-approved GHRH analog that specifically reduces visceral adipose tissue (VAT), originally developed for HIV-associated lipodystrophy.

Growth HormoneEstablished

AOD-9604

C-terminal fragment of human growth hormone marketed for lipolytic effects without the IGF-1 or insulin resistance effects of full-length GH.

Growth HormoneExperimental

CJC-1295 + Ipamorelin

Classic GHRH + GHRP combination that amplifies endogenous GH pulses more than either alone.

Growth HormonePreclinical